Delivery Order SPE2DB20D3103-SPE2DB25FP9J1
- Not listed
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for 90 tablets of Esbriet 801 mg, a pharmaceutical product used in the treatment of pulmonary fibrosis. This firm fixed price, non-set-aside contract was awarded on August 4, 2025, with an ultimate completion date of August 25, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $3,425.95 firm fixed price delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, a pharmaceutical product used to treat idiopathic pulmonary fibrosis. The contract, awarded on July 21, 2025, with an ultimate completion date of August 11, 2025, was competitively awarded without set-aside provisions. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $3,425.95 delivery order on August 13, 2025, for 270 tablets of Esbriet 267 mg, a pulmonary fibrosis medication. This competitively awarded, firm fixed-price contract contains no set-aside designation and is scheduled for completion by September 4, 2025. The pharmaceutical supply will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is a child...
- The Defense Logistics Agency awarded a $17,129.75 delivery order to AmerisourceBergen Drug Corp for 90 tablets of Esbriet 801 mg, a pharmaceutical treatment primarily used for idiopathic pulmonary fibrosis. This firm fixed-price delivery order, which was competitively awarded without set-aside provisions, is scheduled for completion by September 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, leveraging the company's...
- The Defense Logistics Agency awarded a delivery order valued at $3,425.95 to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, a pharmaceutical product used in the treatment of idiopathic pulmonary fibrosis. This firm fixed-price delivery order, issued on August 18, 2025, with an ultimate completion date of September 9, 2025, carries no set-aside designation and was competitively awarded. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $3,425.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Esbriet 801 mg tablets (90-count units) on August 18, 2025, with completion targeted for September 9, 2025. This non-set-aside competitive award is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $1 billion...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price contract utilizes no set-aside designation and represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The pharmaceutical will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a $3,425.95 firm fixed price delivery order to AmerisourceBergen Drug Corp for Esbriet (pirfenidone) 801 mg tablets in a quantity of 90 units. This award, issued on July 21, 2025, with an ultimate completion date of August 11, 2025, represents a non-competitive delivery order under AmerisourceBergen's existing federal contract vehicle. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg on July 30, 2025, with an ultimate completion date of August 20, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Esbriet 801 mg tablets (90-count units) with a ceiling value of $10,277.85. This firm fixed-price delivery order, which must be completed by September 2, 2025, represents a non-competitive set-aside award supporting federal pharmaceutical procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP9J1Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,425.95 for 90 tablets of ESBRIET 801 MG, a pharmaceutical product used in the treatment of idiopathic pulmonary fibrosis. This competitively awarded, firm fixed-price delivery order was issued on August 18, 2025, with an ultimate completion date of September 9, 2025. The contract carries no set-aside designation, indicating it was competed among eligible vendors meeting federal procurement standards. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters. This delivery order represents a task order issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen serves as a critical vendor for federal medical procurement, supplying a comprehensive range of medications and medical supplies to support military and veteran healthcare systems worldwide. The company's role as a prime pharmaceutical vendor enables it to fulfill diverse medical supply requirements across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 8/18/25 |